Market research
PQX1.F Biotage AB
F EUR Healthcare
Latest close
As of 24 Aug 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- 44.54
- Analyst target
- Not available
- Dividend yield
- 13.%
- Beta
- 0.85
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- SE0000454746
- Market cap
- 1B
- P/E ratio
- 44.54
- Analyst target
- Not available
- Dividend yield
- 13.%
- Beta
- 0.85
About
About Biotage AB
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company serves pharmaceutical and biotechnical companies, police and criminal investigators contract research and manufacturing organizations, academic laboratories, hospitals, and sports events, as well as diagnostics, clinical, environmental protection, food safety, clinical, and forensic industries. It operates in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
Research context
Biotage AB appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PQX1.F discussion.
5 years, 7 months ago
Biotage AB is currently in a long term uptrend where the price is trading 40.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.0.
Biotage AB's total revenue rose by 3.3% to $298M since the same quarter in the previous year.
Its net income has increased by 140.1% to $44M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.2% to $80M since the same quarter in the previous year.
Based on the above factors, Biotage AB gets an overall score of 5/5.